recombinant interferon gamma

Phase 3Biologic

NNational Cancer Institute (NCI)

recombinant interferon gamma is one of 330 biologic programs targeting Aspergillosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

329

Competitors

Pipeline

Status by Indication[3][1]

Indication

AspergillosisActive, not recruiting

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

AspergillosisPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

recombinant interferon gamma

NNational Cancer Institute (NCI)

Phase 3

1 2

MS Contin

Merck & Co.

Preclinical

2 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Preclinical

—8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Cancer2 trials

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002505

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed·SSt. Vincent Medical Center - Los Angeles·Phase 2·NCT00002475·40 enrolled

Lymphoma2 trials

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2/3·NCT00070187·24 enrolled

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 3·NCT00003414·50 enrolled

Colorectal Cancer1 trial

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00002796·46 enrolled

Chronic Myelogenous Leukemia1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Withdrawn·—·Phase 1/2·NCT00002761

Melanoma1 trial

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

8 more indications

Breast Cancer1 trial

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 3·NCT00008203

Metastatic Melanoma1 trial

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

Completed·UUniversity of Rochester·Phase 1·NCT00004016

Soft Tissue Sarcoma1 trial

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT01957709·8 enrolled

Prostate Cancer1 trial

Biological Therapy in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002637·25 enrolled

Multiple Myeloma1 trial

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00616720·15 enrolled

Aspergillosis1 trial

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059878

Ovarian Cancer1 trial

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004032·12 enrolled

Peritoneal Cancer1 trial

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00024271

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for recombinant interferon gamma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant interferon gamma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant interferon gamma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

recombinant interferon gamma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Cancer2 trials

Lymphoma2 trials

Colorectal Cancer1 trial

Chronic Myelogenous Leukemia1 trial

Melanoma1 trial

Breast Cancer1 trial

Metastatic Melanoma1 trial

Soft Tissue Sarcoma1 trial

Prostate Cancer1 trial

Multiple Myeloma1 trial

Aspergillosis1 trial

Ovarian Cancer1 trial

Peritoneal Cancer1 trial

References

Drug Info

Quick Facts

Related News